Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 19:10:24 22/07/2026			Varia. 5j.	Varia. 1 janv.
131,79 ^USD	+1,16%		-0,16%	+7,12%

14:52	Ebola : quels vaccins et traitements sont en cours de développement contre la souche Bundibugyo	RE
21/07	L'action Gilead Sciences recule après une dégradation de Leerink Partners	MT

Autres langues

14:52	What Bundibugyo Ebola vaccines and treatments are under development
21/07	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21/07	Gilead Sciences Shares Fall After Downgrade From Leerink Partners
21/07	Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
21/07	Analystenempfehlungen: VAT, Belimo, Richemont, Salesforce, Goldman Sachs, Crowdstrike…
21/07	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
21/07	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
16/07	Kalshi to allow bets on clinical trials, FDA decisions
15/07	African markets - factors to watch on July 15
14/07	Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
08/07	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
08/07	Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
06/07	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
03/07	Trial for Ebola treatment starts in DR Congo
02/07	Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease
02/07	Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
30/06	Africa CDC seeks $18 million in urgent support for Ebola drug trials in DRC
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Growth-Defensive Index
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell Top 200 Growth Benchmark
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 3000E Growth Benchmark
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 3000 Growth Benchmark
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Dynamic Index
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Growth Benchmark
25/06	Major deals involving US drugmakers and biotechs over the past decade
24/06	Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer